{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T20:01:55Z","timestamp":1779998515390,"version":"3.53.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Unione Europea-Next generation EU-PRIN-2022\/PNRR","award":["2022M2HP84"],"award-info":[{"award-number":["2022M2HP84"]}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2021-124872OB-100"],"award-info":[{"award-number":["PID2021-124872OB-100"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cientificas","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Vet Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bluetongue virus (BTV) remains a major threat to livestock health and agricultural economies worldwide due to its multiple serotypes, vector transmission, and wide geographic distribution. Vaccination is essential for controlling BTV outbreaks; however, developing vaccines that provide broad protection while complying with the requirements of differentiating infected from vaccinated animals (DIVA) remains challenging. In this study, we evaluated the antigenicity and protective efficacy of two BTV proteins, VP2 and VP7, delivered using a bovine herpesvirus-4 (BoHV-4)-based viral vector. Groups of mice lacking interferon-\u03b1\/\u03b2 receptor (IFNAR\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    ) (C57BL\/6 background) were immunized using a prime\/boost regimen with BoHV-4 vectors expressing VP2, VP7, or both antigens. All vaccinated groups developed antigen-specific humoral and cellular immune responses. Following challenge with virulent BTV-8, complete protection was observed in the VP2 and VP7 single-antigen groups, while 80% protection was achieved with the combined VP2\u2009+\u2009VP7 vaccination. Total anti-BTV IgG levels increased after booster immunization, with the highest pre-challenge titers detected in the combined vaccination group. After challenge, IgG levels rose further in VP2-immunized mice, whereas VP7-immunized animals showed comparatively lower titers. All vaccinated mice mounted BTV-specific cellular responses, as demonstrated by interferon (IFN)-\u03b3 enzyme-linked immunoadsorption assay (ELISPOT) and intracellular cytokine staining. T cells expressing IFN-\u03b3, IL-2, TNF-\u03b1, or CD107a were detected, with evidence of polyfunctional responses across groups. Notably, VP7 immunization induced stronger cellular responses, including increased cytotoxic potential in CD4\n                    <jats:sup>+<\/jats:sup>\n                    \u2009and CD8\n                    <jats:sup>+<\/jats:sup>\n                    \u2009T cells. These findings demonstrate that BoHV-4 vectors expressing VP2 or VP7 elicit robust humoral and cellular immunity and confer protection against BTV, highlighting their potential as a versatile vaccine platform.\n                  <\/jats:p>","DOI":"10.1186\/s13567-026-01771-5","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T19:04:31Z","timestamp":1779995071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expression of bluetongue virus core proteins VP2 and VP7 by bovine herpesvirus-4 confers protection against virulent challenge in a mouse model"],"prefix":"10.1186","volume":"57","author":[{"given":"Valentina","family":"Franceschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Nogales-Altozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Minesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Donofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"1771_CR1","doi-asserted-by":"publisher","DOI":"10.1051\/vetres:2008023","volume":"39","author":"I Schwartz-Cornil","year":"2008","unstructured":"Schwartz-Cornil I, Mertens P, Contreras V, Hemati B, Pascale F, Br\u00e9ard E, Mellor P, MacLachlan N, Zientara S (2008) Bluetongue virus: virology, pathogenesis and immunity. Vet Res 39:46. https:\/\/doi.org\/10.1051\/vetres:2008023","journal-title":"Vet Res"},{"issue":"2","key":"1771_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1099\/vir.0.82456-0","volume":"88","author":"S Maan","year":"2007","unstructured":"Maan S, Maan N, Samuel A, Rao S, Attoui H, Mertens P (2007) Analysis and phylogenetic comparisons of full-length VP2 genes of the 24 bluetongue virus serotypes. J Gen Virol 88:621\u2013630. https:\/\/doi.org\/10.1099\/vir.0.82456-0","journal-title":"J Gen Virol"},{"key":"1771_CR3","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.1128\/JVI.02284-06","volume":"81","author":"M Forzan","year":"2007","unstructured":"Forzan M, Marsh M, Roy P (2007) Bluetongue virus entry into cells. J Virol 81:4819\u20134827. https:\/\/doi.org\/10.1128\/JVI.02284-06","journal-title":"J Virol"},{"key":"1771_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2021.645561","author":"JM Rojas","year":"2021","unstructured":"Rojas JM, Barba-Moreno D, Avia M, Sevilla N, Mart\u00edn V (2021) Vaccination with recombinant adenoviruses expressing the bluetongue virus subunits VP7 and VP2 provides protection against heterologous virus challenge. Front Vet Sci 8:645561. https:\/\/doi.org\/10.3389\/fvets.2021.645561","journal-title":"Front Vet Sci"},{"issue":"1","key":"1771_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcpa.2009.04.003","volume":"141","author":"N Maclachlan","year":"2009","unstructured":"Maclachlan N, Drew C, Darpel K, Worwa G (2009) The pathology and pathogenesis of bluetongue. J Comp Pathol 141:1\u201316. https:\/\/doi.org\/10.1016\/j.jcpa.2009.04.003","journal-title":"J Comp Pathol"},{"issue":"2","key":"1771_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/1040638715571627","volume":"27","author":"A Allen","year":"2015","unstructured":"Allen A, Stanton J, Evermann J, Fry L, Ackerman M, Barrington G (2015) Bluetongue disease and seroprevalence in South American camelids from the northwestern region of the United States. J Vet Diagn Invest 27:226\u2013230. https:\/\/doi.org\/10.1177\/1040638715571627","journal-title":"J Vet Diagn Invest"},{"key":"1771_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0147-9571(94)90043-4","volume":"17","author":"N MacLachlan","year":"1994","unstructured":"MacLachlan N (1994) The pathogenesis and immunology of bluetongue virus infection of ruminants. Comp Immunol Microbiol Infect Dis 17:197\u2013206. https:\/\/doi.org\/10.1016\/0147-9571(94)90043-4","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"1771_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0147-9571(94)90044-2","volume":"17","author":"E Gibbs","year":"1994","unstructured":"Gibbs E, Greiner E (1994) The epidemiology of bluetongue. Comp Immunol Microbiol Infect Dis 17:207\u2013220. https:\/\/doi.org\/10.1016\/0147-9571(94)90044-2","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"4","key":"1771_CR9","doi-asserted-by":"publisher","first-page":"e4533","DOI":"10.1002\/vetr.4533","volume":"195","author":"K van den Brink","year":"2024","unstructured":"van den Brink K, Santman-Berends I, Harkema L, Scherpenzeel C, Dijkstra E, Bisschop P,\u00a0Peterson K, van de Burgwal NS, Waldeck HWF, Dijkstra T, Holwerda M, Spierenburg MAH, van den Brom R (2024) Bluetongue virus serotype 3 in ruminants in the Netherlands: clinical signs, seroprevalence and pathological findings. Vet Rec 195:e4533. https:\/\/doi.org\/10.1002\/vetr.4533","journal-title":"Vet Rec"},{"key":"1771_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/vetr.4910","author":"K Newbrook","year":"2024","unstructured":"Newbrook K, Obishakin E, Jones LA, Waters R, Ashby M, Batten C, Sanders C (2024) Clinical disease in British sheep infected with an emerging strain of bluetongue virus serotype 3. Vet Rec 196:e4910. https:\/\/doi.org\/10.1002\/vetr.4910","journal-title":"Vet Rec"},{"key":"1771_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2024.110365","volume":"301","author":"R van DeBrom","year":"2025","unstructured":"van DeBrom R, Holwerda M (2025) Bluetongue virus serotype 12 in sheep and cattle in the Netherlands in 2024\u2014a BTV serotype reported in Europe for the first time. Vet Microbiol 301:110365. https:\/\/doi.org\/10.1016\/j.vetmic.2024.110365","journal-title":"Vet Microbiol"},{"issue":"1","key":"1771_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microorganisms9010042","volume":"9","author":"L Jim\u00e9nez-Cabello","year":"2021","unstructured":"Jim\u00e9nez-Cabello L, Utrilla-Trigo S, Calvo-Pinilla E, Moreno S, Nogales A, Ortego J, Mar\u00edn-L\u00f3pez A (2021) Viral vector vaccines against bluetongue virus. Microorganisms 9:42. https:\/\/doi.org\/10.3390\/microorganisms9010042","journal-title":"Microorganisms"},{"key":"1771_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2052","author":"P Roy","year":"2009","unstructured":"Roy P, Boyce M, Noad R (2009) Prospects for improved bluetongue vaccines. Nat Rev Microbiol 7:120\u2013128. https:\/\/doi.org\/10.1038\/nrmicro2052","journal-title":"Nat Rev Microbiol"},{"key":"1771_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10111528","volume":"10","author":"J Rojas","year":"2021","unstructured":"Rojas J, Mart\u00edn V, Sevilla N (2021) Vaccination as a strategy to prevent bluetongue virus vertical transmission. Pathogens 10:1528. https:\/\/doi.org\/10.3390\/pathogens10111528","journal-title":"Pathogens"},{"issue":"Suppl. 4","key":"1771_CR15","doi-asserted-by":"publisher","first-page":"D86","DOI":"10.1016\/j.vaccine.2009.08.037","volume":"27","author":"R Noad","year":"2009","unstructured":"Noad R, Roy P (2009) Bluetongue vaccines. Vaccine 27:D86\u2013D89. https:\/\/doi.org\/10.1016\/j.vaccine.2009.08.037","journal-title":"Vaccine"},{"key":"1771_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4149\/av_2019_109","volume":"63","author":"K Ranjan","year":"2019","unstructured":"Ranjan K, Prasad M, Brar B, Lambe U, Kumar R, Ghosh M, Prasad G (2019) Bluetongue virus vaccine: conventional to modern approach. Acta Virol 63:3\u201318. https:\/\/doi.org\/10.4149\/av_2019_109","journal-title":"Acta Virol"},{"key":"1771_CR17","doi-asserted-by":"publisher","unstructured":"Mart\u00edn V, Pascual E, Avia M, Pe\u00f1a L, Valc\u00e1rcel F, Sevilla N (2015) Protective efficacy in sheep of adenovirus-vectored vaccines against bluetongue virus is associated with specific T cell responses. PLoS One 10:e0143273. https:\/\/doi.org\/10.1371\/journal.pone.0143273","DOI":"10.1371\/journal.pone.0143273"},{"issue":"2","key":"1771_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.vaccine.2009.10.027","volume":"28","author":"E Calvo-Pinilla","year":"2009","unstructured":"Calvo-Pinilla E, Rodr\u00edguez-Calvo T, Sevilla N, Ortego J (2009) Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-\/-) mice against lethal bluetongue infection. Vaccine 28:437\u2013445. https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.027","journal-title":"Vaccine"},{"issue":"3\u20134","key":"1771_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0165-2427(97)00084-6","volume":"59","author":"Z Lobato","year":"1997","unstructured":"Lobato Z, Coupar B, Gray C, Lunt R, Andrew M (1997) Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. Vet Immunol Immunopathol 59:293\u2013309. https:\/\/doi.org\/10.1016\/s0165-2427(97)00084-6","journal-title":"Vet Immunol Immunopathol"},{"key":"1771_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.vaccine.2006.08.025","volume":"25","author":"J Boone","year":"2007","unstructured":"Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, Nordgren R, Monaco F, Savini G, Gardner IA, Maclachlan NJ\u00a0(2007) Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25:672\u2013678.\u00a0https:\/\/doi.org\/10.1016\/j.vaccine.2006.08.025","journal-title":"Vaccine"},{"key":"1771_CR21","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.vaccine.2011.12.108","volume":"30","author":"S Top","year":"2012","unstructured":"Top S, Foucras G, Deplanche M, Rives G, Calvalido J,\u00a0Comtet L, Bertagnoli S, Meyer G (2012) Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus. Vaccine 30:1609\u20131616.\u00a0https:\/\/doi.org\/10.1016\/j.vaccine.2011.12.108","journal-title":"Vaccine"},{"issue":"7","key":"1771_CR22","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1099\/0022-1317-78-7-1611","volume":"78","author":"A Wade-Evans","year":"1997","unstructured":"Wade-Evans A, Pullen L, Hamblin C, O\u2019Hara R, Burroughs J, Mertens P (1997) African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge. J Gen Virol 78:1611\u20131616.\u00a0https:\/\/doi.org\/10.1099\/0022-1317-78-7-1611","journal-title":"J Gen Virol"},{"issue":"3","key":"1771_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines8030346","volume":"8","author":"S Utrilla-Trigo","year":"2020","unstructured":"Utrilla-Trigo S, Jim\u00e9nez-Cabello L, Alonso-Ravelo R, Calvo-Pinilla E, Mar\u00edn-L\u00f3pez A, Moreno S, Lorenzo G, Benavides J, Gilbert S, Nogales A, Ortego J (2020) Heterologous combination of chadox1 and MVA vectors expressing protein NS1 as vaccination strategy to induce durable and cross-protective CD8+ T cell immunity to bluetongue virus. Vaccines 8:346. https:\/\/doi.org\/10.3390\/vaccines8030346","journal-title":"Vaccines"},{"key":"1771_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111605","author":"C Bouet-Cararo","year":"2014","unstructured":"Bouet-Cararo C, Contreras V, Caruso A, Top S, Szelechowski M, Bergeron C, Viarouge C, Desprat A, Relmy A, Guibert JM, Dubois E, Thiery R, Br\u00e9ard E, Bertagnoli S, Richardson J, Foucras G, Meyer G, Schwartz-Cornil I, Zientara S, Klonjkowski B (2014) Expression of VP7, a bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep. PLoS One 9:e111605. https:\/\/doi.org\/10.1371\/journal.pone.0111605","journal-title":"PLoS ONE"},{"key":"1771_CR25","doi-asserted-by":"publisher","first-page":"8339","DOI":"10.1128\/JVI.00808-08","volume":"82","author":"M Boyce","year":"2008","unstructured":"Boyce M, Celma C, Roy P (2008) Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts. J Virol 82:8339\u20138348. https:\/\/doi.org\/10.1128\/JVI.00808-08","journal-title":"J Virol"},{"key":"1771_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ymeth.2012.05.012","volume":"59","author":"S Trask","year":"2013","unstructured":"Trask S, Boehme K, Dermody T, Patton J (2013) Comparative analysis of reoviridae reverse genetics methods. Methods 59:199\u2013206. https:\/\/doi.org\/10.1016\/j.ymeth.2012.05.012","journal-title":"Methods"},{"key":"1771_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/v13050857","volume":"13","author":"P van Rijn","year":"2021","unstructured":"van Rijn P, Maris-Veldhuis M, van Gennip R (2021) The Bluetongue disabled infectious single animal (DISA) vaccine platform based on deletion NS3\/NS3A protein is safe and protective in cattle and enables DIVA. Viruses 13:857. https:\/\/doi.org\/10.3390\/v13050857","journal-title":"Viruses"},{"key":"1771_CR28","doi-asserted-by":"publisher","first-page":"10213","DOI":"10.1128\/JVI.05412-11","volume":"85","author":"E Matsuo","year":"2011","unstructured":"Matsuo E, Celma C, Boyce M, Viarouge C, Sailleau C, Dubois E, Br\u00e9ard E, Thi\u00e9ry R, Zientara S, Roy P (2011) Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge. J Virol 85:10213\u201310221. https:\/\/doi.org\/10.1128\/JVI.05412-11","journal-title":"J Virol"},{"key":"1771_CR29","doi-asserted-by":"publisher","first-page":"9856","DOI":"10.1128\/JVI.01514-13","volume":"87","author":"C Celma","year":"2013","unstructured":"Celma C, Boyce M, van Rijn P, Eschbaumer M, Wernike K, Hoffmann B, Beer M, Haegeman A, De Clercq K, Roy P (2013) Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep. J Virol 87:9856\u20139864. https:\/\/doi.org\/10.1128\/JVI.01514-13","journal-title":"J VirolVirol"},{"issue":"3","key":"1771_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/spectrum.02493-23","volume":"12","author":"S Utrilla-Trigo","year":"2024","unstructured":"Utrilla-Trigo S, Jim\u00e9nez-Cabello L, Mar\u00edn-L\u00f3pez A, Illescas-Amo M, Andr\u00e9s G, Calvo-Pinilla E, Lorenzo G, van Rijn PA, Ortego J, Nogales A (2024) Engineering recombinant replication-competent bluetongue viruses expressing reporter genes for in\u00a0vitro and non-invasive in\u00a0vivo studies. Microbiol Spectr 12:e0249323. https:\/\/doi.org\/10.1128\/spectrum.02493-23","journal-title":"Microbiol Spectr"},{"issue":"11","key":"1771_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13110944","volume":"13","author":"PR Sinha","year":"2024","unstructured":"Sinha PR, Hegde SR, Mittal R, Jagat CC, Gowda U, Chandrashekhar R, Muthaiah G, Shamshad S, Chanda MM, Ganji V, Putty K, Hemadri D (2024) In silico development of a multi-epitope subunit vaccine against bluetongue virus in Ovis aries using immunoinformatics. Pathogens 13:944. https:\/\/doi.org\/10.3390\/pathogens13110944","journal-title":"Pathogens"},{"issue":"July","key":"1771_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2024.1424307","volume":"15","author":"HB Kolla","year":"2024","unstructured":"Kolla HB, Dutt M, Kumar A, Hebbandi Nanjunadappa R, Karakach T, Singh KP, Kelvin D, Clement Mertens PP, Umeshappa CS (2024) Immuno-informatics study identifies conserved T cell epitopes in non-structural proteins of bluetongue virus serotypes: formulation of a computationally optimized next-generation broad-spectrum multi-epitope vaccine. Front Immunol 15:1424307. https:\/\/doi.org\/10.3389\/fimmu.2024.1424307","journal-title":"Front Immunol"},{"key":"1771_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-7-83","volume":"7","author":"G Donofrio","year":"2009","unstructured":"Donofrio G, Franceschi V, Capocefalo A, Cavirani S, Sheldon I (2009) Isolation and characterization of bovine herpesvirus 4 (BoHV-4) from a cow affected by post partum metritis and cloning of the genome as a bacterial artificial chromosome. Reprod Biol Endocrinol 7:83. https:\/\/doi.org\/10.1186\/1477-7827-7-83","journal-title":"Reprod Biol Endocrinol"},{"key":"1771_CR34","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1128\/CVI.00224-09","volume":"16","author":"G Donofrio","year":"2009","unstructured":"Donofrio G, Franceschi V, Capocefalo A, Taddei S, Sartori C, Bonomini S,\u00a0Cavirani S, Cabassi CS, Flammini CF\u00a0(2009) Cellular targeting of engineered heterologous antigens is a determinant factor for bovine herpesvirus 4-based vaccine vector development. Clin Vaccine Immunol 16:1675\u20131686. https:\/\/doi.org\/10.1128\/CVI.00224-09","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"1771_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005171","volume":"4","author":"E Calvo-Pinilla","year":"2009","unstructured":"Calvo-Pinilla E, Rodriguez-Calvo T, Anguita J, Sevilla N, Ortego J (2009) Establishment of a bluetongue virus infection model in mice that are deficient in the alpha\/beta interferon receptor. PLoS One 4:e5171. https:\/\/doi.org\/10.1371\/journal.pone.0005171","journal-title":"PLoS ONE"},{"key":"1771_CR36","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1099\/vir.0.023192-0","volume":"91","author":"M Thirion","year":"2010","unstructured":"Thirion M, Machiels B, Faranir F, Donofrio G, Gillet L, Dewals B, Vanderplasschen A (2010) Bovine herpesvirus 4 ORF73 is dispensable for virus growth in\u00a0vitro, but is essential for virus persistence in\u00a0vivo. J Gen Virol 91:2574\u20132584. https:\/\/doi.org\/10.1099\/vir.0.023192-0","journal-title":"J Gen Virol"},{"key":"1771_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00421","volume":"9","author":"F Macchi","year":"2018","unstructured":"Macchi F, Rojas J, Verna A, Sevilla N, Franceschi V, Tebaldi G, Cavirani S, Mart\u00edn V, Donofrio G (2018) Bovine herpesvirus-4-based vector delivering peste des petits ruminants virus hemagglutinin ORF induces both neutralizing antibodies and cytotoxic T cell responses. Front Immunol 9:421. https:\/\/doi.org\/10.3389\/fimmu.2018.00421","journal-title":"Front Immunol"},{"key":"1771_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705539","volume":"12","author":"D Rodr\u00edguez-Mart\u00edn","year":"2021","unstructured":"Rodr\u00edguez-Mart\u00edn D, Rojas JM, Macchi F, Franceschi V, Russo L, Sevilla N, Donofr\u00edo G, Mart\u00edn V (2021) Immunization with bovine herpesvirus-4-based vector delivering PPRV-H protein protects sheep from PPRV challenge. Front Immunol 12:705539. https:\/\/doi.org\/10.3389\/fimmu.2021.705539","journal-title":"Front Immunol"},{"issue":"16","key":"1771_CR39","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1016\/j.vaccine.2011.01.075","volume":"29","author":"V Franceschi","year":"2011","unstructured":"Franceschi V, Capocefalo A, Calvo-Pinilla E, Redaelli M, Mucignat-Caretta C, Mertens P, Ortego J, Donofrio G (2011) Immunization of knock-out \u03b1\/\u03b2 interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen. Vaccine 29:3074\u20133082. https:\/\/doi.org\/10.1016\/j.vaccine.2011.01.075","journal-title":"Vaccine"},{"issue":"48","key":"1771_CR40","doi-asserted-by":"publisher","first-page":"6031","DOI":"10.1016\/j.vaccine.2008.09.023","volume":"26","author":"G Donofrio","year":"2008","unstructured":"Donofrio G, Sartori C, Franceschi V, Capocefalo A, Cavirani S, Taddei S, Flammini CF (2008) Double immunization strategy with a BoHV-4-vectorialized secreted chimeric peptide BVDV-E2\/BoHV-1-gD. Vaccine 26:6031\u20136042. https:\/\/doi.org\/10.1016\/j.vaccine.2008.09.023","journal-title":"Vaccine"},{"key":"1771_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.07.061","author":"JM Rojas","year":"2011","unstructured":"Rojas JM, Rodr\u00edguez-Calvo T, Pe\u00f1a L, Sevilla N (2011) T cell responses to bluetongue virus are directed against multiple and identical CD4 + and CD8 + T cell epitopes from the VP7 core protein in mouse and sheep. Vaccine\u00a029:6848-6857.\u00a0https:\/\/doi.org\/10.1016\/j.vaccine.2011.07.061","journal-title":"Vaccine"},{"issue":"1","key":"1771_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1297-9716-45-30","volume":"45","author":"JM Rojas","year":"2014","unstructured":"Rojas JM, Pe\u00f1a L, Mart\u00edn V, Sevilla N (2014) Ovine and murine T cell epitopes from the non-structural protein 1 (NS1) of bluetongue virus serotype 8 (BTV-8) are shared among viral serotypes. Vet Res 45:30. https:\/\/doi.org\/10.1186\/1297-9716-45-30","journal-title":"Vet Res"},{"issue":"1\u20132","key":"1771_CR43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0166-0934(01)00419-0","volume":"101","author":"G Donofrio","year":"2002","unstructured":"Donofrio G, Cavirani S, Simone T, Van Santen VL (2002) Potential of bovine herpesvirus 4 as a gene delivery vector. J Virol Methods 101:49\u201361. https:\/\/doi.org\/10.1016\/S0166-0934(01)00419-0","journal-title":"J Virol Methods"},{"key":"1771_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/science.8009221","author":"U M\u00fcller","year":"1994","unstructured":"M\u00fcller U, Steinhoff U, Reis LFL, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M (1994) Functional role of type I and type II interferons in antiviral defense. Science 264:1918\u20131921. https:\/\/doi.org\/10.1126\/science.8009221","journal-title":"Science"},{"key":"1771_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4103\/0976-500X.119726","volume":"4","author":"J Charan","year":"2013","unstructured":"Charan J, Kantharia N (2013) How to calculate sample size in animal studies? Pharmacol Pharmacother 4:303\u2013306. https:\/\/doi.org\/10.4103\/0976-500X.119726","journal-title":"Pharmacol Pharmacother"},{"issue":"7","key":"1771_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101226","volume":"9","author":"J Rojas","year":"2014","unstructured":"Rojas J, Moreno H, Valc\u00e1rcel F, Pe\u00f1a L, Sevilla N, Mart\u00edn V (2014) Vaccination with recombinant adenoviruses expressing the peste des petits ruminants virus F or H proteins overcomes viral immunosuppression and induces protective immunity against PPRV challenge in sheep. PLoS One 9:e101226. https:\/\/doi.org\/10.1371\/journal.pone.0101226","journal-title":"PLoS ONE"},{"issue":"9","key":"1771_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13090991","volume":"13","author":"P Nogales-Altozano","year":"2025","unstructured":"Nogales-Altozano P, G\u00f3mez-Marcos L, Carl\u00f3n AB, Louloudes-L\u00e1zaro A, Rivera-Rodr\u00edguez A, Larraga J, Alcolea PJ, Alonso A, Larraga V, Mart\u00edn V, Rojas JM, Sevilla N (2025) Expressing bluetongue virus VP2 and VP7 proteins protects against virulent challenge. Vaccines 13:991. https:\/\/doi.org\/10.3390\/vaccines13090991","journal-title":"Vaccines"},{"issue":"2","key":"1771_CR48","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1128\/JVI.02697-13","volume":"88","author":"T Rodr\u00edguez-Calvo","year":"2014","unstructured":"Rodr\u00edguez-Calvo T, Rojas JM, Mart\u00edn V, Sevilla N (2014) Type I interferon limits the capacity of bluetongue virus to infect hematopoietic precursors and dendritic cells in\u00a0vitro and in\u00a0vivo. J Virol 88:859\u2013867. https:\/\/doi.org\/10.1128\/JVI.02697-13","journal-title":"J Virol"},{"issue":"40","key":"1771_CR49","doi-asserted-by":"publisher","first-page":"6848","DOI":"10.1016\/j.vaccine.2011.07.061","volume":"29","author":"JM Rojas","year":"2011","unstructured":"Rojas JM, Rodr\u00edguez-Calvo T, Pe\u00f1a L, Sevilla N (2011) T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep. Vaccine 29:6848\u20136857. https:\/\/doi.org\/10.1016\/j.vaccine.2011.07.061","journal-title":"Vaccine"},{"issue":"1\u20132","key":"1771_CR50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF01314453","volume":"72","author":"I Gumm","year":"1982","unstructured":"Gumm I, Newman J (1982) The preparation of purified bluetongue virus group antigen for use as a diagnostic reagent. Arch Virol 72:83\u201393. https:\/\/doi.org\/10.1007\/BF01314453","journal-title":"Arch Virol"},{"key":"1771_CR51","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1016\/j.vaccine.2015.03.067","volume":"33","author":"DM Legisa","year":"2015","unstructured":"Legisa DM, Perez Aguirreburualde MS, Gonzalez FN, Marin-Lopez A, Ruiz V, Wigdorovitz A, Martinez-Escribano JA, Ortego J, Dus Santos MJ (2015) An experimental subunit vaccine based on bluetongue virus 4 VP2protein fused to an antigen-presenting cells single chain antibodyelicits cellular and humoral immune responses in cattle, guinea pigs and IFNAR(\u2212\/\u2212) mice. Vaccine 33:2614\u20132619. https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.067","journal-title":"Vaccine"},{"key":"1771_CR52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jare.2021.01.007","volume":"31","author":"M Saminathan","year":"2021","unstructured":"Saminathan M, Pal Singh K, Maity M, Vineetha S, Manjunathareddy GB, Dhama K, Malik YS, Ramakrishnan MA, Misri J, Gupta VK (2021) Pathological and immunological characterization of bluetongue virus serotype 1 infection in type I interferons blocked immunocompetent adult mice. J Adv Res 31:137\u201353","journal-title":"J Adv Res"},{"key":"1771_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/v13112208","volume":"13","author":"H Attoui","year":"2021","unstructured":"Attoui H, Monsion B, Klonjkowski B, Zientara S, Mertens PPC, Jaafar FM (2021) Identification of the genome segments of bluetongue virus type 26\/type 1 reassortants influencing horizontal transmission in a mouse model. Viruses 13:2208. https:\/\/doi.org\/10.3390\/v13112208","journal-title":"Viruses"},{"key":"1771_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/v16091474","volume":"16","author":"BS Drolet","year":"2024","unstructured":"Drolet BS, Reinster-Hendricks L, Mayo C, Rodgers C, Molik DC, Scott McVey D (2024) Increased virulence of Culicoides midge cell-derived bluetongue virus in IFNAR mice. Viruses 16:1474. https:\/\/doi.org\/10.3390\/v16091474","journal-title":"Viruses"},{"key":"1771_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2024.110365","author":"R van den Brom","year":"2025","unstructured":"van den Brom R, Santman-Berends I, van der Heijden MG, Harders F, Engelsma M, van Gennip RGP, Maris-Veldhuis MA, Feddema AJ, Peterson K, Golender N, Spierenburg M, van Rijn PA, Holwerda M (2025) Bluetongue virus serotype 12 in sheep and cattle in the Netherlands in 2024\u2014a BTV serotype reported in Europe for the first time. Vet Microbiol 301:110365. https:\/\/doi.org\/10.1016\/j.vetmic.2024.110365","journal-title":"Vet Microbiol"},{"key":"1771_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034425","volume":"7","author":"G Ma","year":"2012","unstructured":"Ma G, Eschbaumer M, Said A, Hoffmann B, Beer M, Osterrieder N (2012) An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. PLoS One 7:e34425","journal-title":"PLoS ONE"},{"key":"1771_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-020-00218-y","volume":"5","author":"E Calvo-Pinilla","year":"2020","unstructured":"Calvo-Pinilla E, Mar\u00edn-L\u00f3pez A, Moreno S, Lorenzo G, Utrilla-Trigo S, Jim\u00e9nez-Cabello L, Benavides J, Nogales A, Blasco R, Brun A, Ortego J (2020) A protective bivalent vaccine against Rift Valley fever and bluetongue. NPJ Vaccines 5:70. https:\/\/doi.org\/10.1038\/s41541-020-00218-y","journal-title":"NPJ Vaccines"},{"key":"1771_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060574","volume":"8","author":"T Jabbar","year":"2013","unstructured":"Jabbar T, Calvo-Pinilla E, Mateos F, Gubbins S, Bin-Tarif A, Bachanek-Bankowska K, Alpar O, Ortego J, Takamatsu HH, Mertens PPC (2013) Protection of IFNAR (\u2212\/\u2212) mice against bluetongue virus serotype 8, by heterologous (DNA\/rMVA) and homologous (rMVA\/rMVA) vaccination, expressing outer-capsid protein VP2. PLoS One 8:e60574. https:\/\/doi.org\/10.3390\/pathogens12040602","journal-title":"PLoS ONE"},{"key":"1771_CR59","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1006\/viro.1996.0306","volume":"220","author":"A Wade-Evans","year":"1996","unstructured":"Wade-Evans A, Romero C, Mellor P, Takamatsu H, Anderson J, Thevasagayam J, Fleming M, Mertens P, Black D (1996) Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology 220:227\u2013231.  https:\/\/doi.org\/10.1006\/viro.1996.0306","journal-title":"Virology"},{"key":"1771_CR60","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1016\/j.vaccine.2007.06.052","volume":"25","author":"A Perrin","year":"2007","unstructured":"Perrin A, Albina E, Br\u00e9ard E, Sailleau C, Prom\u00e9 S, Grillet C, Kwiatek O, Russo P, Thi\u00e9ry R, Zientara S, Al E (2007) Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine 25:6774\u20136783. https:\/\/doi.org\/10.1016\/j.vaccine.2007.06.052","journal-title":"Vaccine"},{"key":"1771_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.6","volume":"5","author":"C Macri","year":"2016","unstructured":"Macri C, Dumont C, Johnston AP, Mintern JD (2016) Targeting dendritic cells: a promising strategy to improve vaccine effectiveness. Clin Transl Immunol 5:e66. https:\/\/doi.org\/10.1038\/cti.2016.6","journal-title":"Clin Transl Immunol"},{"key":"1771_CR62","doi-asserted-by":"publisher","first-page":"645210","DOI":"10.3389\/fimmu.2021.645210","volume":"12","author":"P Rosenbaum","year":"2021","unstructured":"Rosenbaum P, Tchitchek N, Joly C, Rodriguez Pozo A, Stimmer L, Langlois S, Hocini H, Gosse L, Pejoski D, Cosma A, Beignon A-S, Dereuddre-Bosquet N, Levy Y, Le Grand R, Martinon F (2021) Vaccine inoculation route modulates early immunity and consequently antigen-specific immune response. Front Immunol 12:645210. https:\/\/doi.org\/10.3389\/fimmu.2021.645210","journal-title":"Front Immunol"},{"key":"1771_CR63","unstructured":"Detailed protocols for recombineering can also be found at the recombineering website (https:\/\/redrecombineering.ncifcrf.gov\/). This is the original Court laboratory recombineering website. Although no longer regularly updated, it contains valuable information about recombineering in E. coli."}],"container-title":["Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13567-026-01771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13567-026-01771-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13567-026-01771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T19:04:33Z","timestamp":1779995073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13567-026-01771-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1771"],"URL":"https:\/\/doi.org\/10.1186\/s13567-026-01771-5","relation":{},"ISSN":["1297-9716"],"issn-type":[{"value":"1297-9716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the animal experiments were carried out in a disease-secure isolation facility (biosecurity level 3) at the Centro de Investigaci\u00f3n en Sanidad Animal (CISA), in strict accordance with the recommendations in the guidelines of the Code for Methods and Welfare Considerations in Behavioral Research with Animals (Directive 86\/609EC; RD1201\/2005), and all efforts were made to minimize suffering. Experiments were approved by the Committees on the Ethics of Animal Experiments of the Consejo Superior de Investigaciones Cient\u00edficas (CSIC) and the National Animal Welfare Committee (PROEX 190.7\/24).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}